Patheon markets transatlantic cov-lite for DSM merger
Toronto-listed pharmaceuticals firm Patheon is in the market for a $1.15bn-equivalent seven year covenant-lite loan package.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
